Avadel Pharmaceuticals (AVDL) Projected to Post Quarterly Earnings on Monday

by · The Cerbat Gem

Avadel Pharmaceuticals (NASDAQ:AVDL – Get Free Report) is projected to release its Q4 2025 results before the market opens on Monday, March 2nd. Analysts expect Avadel Pharmaceuticals to post earnings of $0.09 per share for the quarter. Interested persons can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Wednesday, March 11, 2026 at 4:00 PM ET.

Avadel Pharmaceuticals Stock Performance

NASDAQ AVDL opened at $21.39 on Friday. Avadel Pharmaceuticals has a fifty-two week low of $6.38 and a fifty-two week high of $23.57. The business has a 50 day moving average price of $21.51 and a two-hundred day moving average price of $18.99.

Hedge Funds Weigh In On Avadel Pharmaceuticals

Large investors have recently modified their holdings of the stock. Raymond James Financial Inc. bought a new stake in Avadel Pharmaceuticals in the second quarter valued at about $65,000. Tower Research Capital LLC TRC grew its position in shares of Avadel Pharmaceuticals by 217.5% in the 2nd quarter. Tower Research Capital LLC TRC now owns 8,795 shares of the company’s stock worth $78,000 after acquiring an additional 6,025 shares in the last quarter. Prudential Financial Inc. acquired a new position in shares of Avadel Pharmaceuticals in the 2nd quarter worth approximately $96,000. Dynamic Technology Lab Private Ltd bought a new stake in shares of Avadel Pharmaceuticals in the 1st quarter valued at approximately $115,000. Finally, CIBC Private Wealth Group LLC acquired a new stake in shares of Avadel Pharmaceuticals during the 3rd quarter valued at approximately $122,000. Institutional investors own 69.19% of the company’s stock.

Analyst Ratings Changes

A number of research firms have recently commented on AVDL. Weiss Ratings reissued a “sell (d-)” rating on shares of Avadel Pharmaceuticals in a research report on Monday, December 29th. Zacks Research upgraded shares of Avadel Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Tuesday, January 6th. Finally, Wells Fargo & Company upped their price objective on shares of Avadel Pharmaceuticals from $20.00 to $22.50 and gave the company an “equal weight” rating in a research report on Thursday, November 20th. One research analyst has rated the stock with a Buy rating, ten have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $20.00.

View Our Latest Research Report on AVDL

About Avadel Pharmaceuticals

(Get Free Report)

Avadel Pharmaceuticals plc is a global specialty biopharmaceutical company focused on developing and delivering treatments for rare diseases and central nervous system disorders. Headquartered in Dublin, Ireland, with operations in the United States, Avadel’s portfolio centers on sleep disorder therapeutics, including its flagship low-sodium oxybate product, XYWAV, which is approved in the U.S. for the treatment of cataplexy or excessive daytime sleepiness in patients with narcolepsy. The company is also advancing FT218, a once-nightly formulation of sodium oxybate, currently under regulatory review for narcolepsy management.

Formed through a rebranding of Flamel Technologies in 2016 and a strategic shift toward rare disease drug development, Avadel has built its R&D capabilities around improving patient compliance and reducing daily sodium exposure compared to traditional therapies.

Featured Articles